drugset

drugset / Trial / NCT02713529

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

NCT02713529 ↗

Phase 1/2 Completed 117 enrolled AmMax Bio, Inc. Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.

Timeline

Start: 2016-04-14
Primary completion: 2019-01-02
Completion: 2019-05-17

Publications

Background Razak AR, Cleary JM, Moreno V, Boyer M, Calvo Aller E, Edenfield W, Tie J, Harvey RD, Rutten A, Shah MA, Olszanski AJ, Jager D, Lakhani N, Ryan DP, Rasmussen E, Juan G, Wong H, Soman N, Smit MD, Nagorsen D, Papadopoulos KP. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J Immunother Cancer. 2020 Oct;8(2):e001006. doi: 10.1136/jitc-2020-001006.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMG 820	Monoclonal antibody	—	—
Background	Pembrolizumab	Monoclonal antibody	—	—

Indications